References

Idiopathic inflammatory myopathies

10.1038/s41572-021-00321-x · 2021 · External reference

Long-term outcome in polymyositis and dermatomyositis

10.1136/ard.2005.045690 · 2006 · External reference

Frequency of relapses in patients with polymyositis and dermatomyositis

10.1002/(sici)1097-4598(199812)21:12<1668::aid-mus7>3.0.co;2-# · 1998 · External reference

Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies

10.1093/rheumatology/40.11.1262 · 2001 · External reference

The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League against rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study

10.1002/art.23248 · 2008 · External reference

Update on outcome assessment in myositis

10.1038/nrrheum.2018.33 · 2018 · External reference

The EuroMyositis registry: an international collaborative tool to facilitate myositis research

10.1136/annrheumdis-2017-211868 · 2018 · External reference

Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis

2005 · External reference

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

10.1111/j.1365-2133.2008.08711.x · 2008 · External reference

Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change

10.1111/bjd.13915 · 2015 · External reference

Characterization of relapses in adult idiopathic inflammatory myopathies

10.1007/s10067-005-0075-3 · 2006 · External reference

Dermatomyositis: factors predicting relapse

10.1111/jdv.13516 · 2016 · External reference

Predictive factors for relapse in adults with dermatomyositis

2020 · External reference

Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis

10.1080/14397595.2017.1317377 · 2018 · External reference

Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis

2001 · External reference

Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort

10.1007/s00296-020-04779-y · 2021 · External reference

Prognostic implications of myositis-specific autoantibodies on mortality, relapse, and remission in dermatomyositis patients

10.1111/ene.70446 · 2025 · External reference

Preliminary definition of cutaneous flare in dermatomyositis: a retrospective review

10.1016/j.jaad.2022.03.054 · 2023 · External reference

Type I interferon pathway in adult and juvenile dermatomyositis

10.1186/ar3531 · 2011 · External reference

Management of cutaneous dermatomyositis: management of cutaneous dermatomyositis

10.1111/j.1529-8019.2012.01491.x · 2012 · External reference

Environmental triggers of dermatomyositis: a narrative review

10.21037/atm-20-3719 · 2021 · External reference

Seasonal occurrence of relapses in inflammatory myopathies: a preliminary study

10.1007/s004150200036 · 2002 · External reference

Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome

10.1093/rheumatology/41.9.1040 · 2002 · External reference

Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy

10.1212/nxi.0000000000000096 · 2015 · External reference

Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study

10.1007/s10067-017-3854-8 · 2018 · External reference

Clinical features and recurrence risk prediction model in patients with idiopathic inflammatory myopathies-associated interstitial lung disease: a retrospective study from Ningbo

10.3389/fmed.2025.1666332 · 2025 · External reference

Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease

10.1016/j.resinv.2019.10.004 · 2020 · External reference

Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort

10.1136/rmdopen-2023-003121 · 2023 · External reference

Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies

10.3389/fimmu.2024.1404828 · 2024 · External reference

Quantitative interstitial lung disease scores in idiopathic inflammatory myopathies: longitudinal changes and clinical implications

10.1093/rheumatology/kead122 · 2023 · External reference

Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease

10.3389/fimmu.2022.872615 · 2022 · External reference

Validation of cutaneous dermatomyositis disease area and severity index activity score and other efficacy outcomes as measures of skin disease in dermatomyositis in the lenabasum phase 3 trial

10.1016/j.jid.2023.05.025 · 2023 · External reference

Acute exacerbation of interstitial lung disease in adult patients with idiopathic inflammatory myopathies: a retrospective case-control study

10.3389/fmed.2020.00012 · 2020 · External reference

The clinical features and prognosis of idiopathic and infection-triggered acute exacerbation of idiopathic inflammatory myopathy-associated interstitial lung disease: a preliminary study

10.3390/diagnostics15192516 · 2025 · External reference

Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography, a prospective cohort study

10.1186/s12890-025-03962-w · 2025 · External reference

Predictive risk factors for one-year mortality in idiopathic inflammatory myopathy patients with interstitial lung disease: a retrospective, single-center cohort study

10.46497/archrheumatol.2024.10418 · 2024 · External reference

Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy

10.1186/s12890-016-0325-y · 2016 · External reference

Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody

10.1016/j.semarthrit.2011.09.008 · 2012 · External reference

Poor prognostic factors for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies after combination therapy

10.3389/fimmu.2024.1407633 · 2024 · External reference

Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases

10.1093/rheumatology/keaa372 · 2021 · External reference

Myositis-associated interstitial lung disease

10.1097/mcp.0000000000001000 · 2023 · External reference

Myositis-associated interstitial lung disease: the experience of a tertiary center

10.3390/jcm13206085 · 2024 · External reference

Progressive pulmonary fibrosis in myositis-specific antibody-positive interstitial pneumonia: a retrospective cohort study

10.3389/fmed.2023.1325082 · 2023 · External reference

Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical–serological–pathological classification

10.1093/rheumatology/keae361 · 2025 · External reference

Idiopathic inflammatory myopathies overlapping with systemic diseases

10.5414/np301077 · 2018 · External reference

Scleromyositis: a distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis

10.3389/fimmu.2022.974078 · 2022 · External reference

Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use

2020 · External reference

Work ability in patients with polymyositis and dermatomyositis: an explorative and descriptive study

2015 · External reference

Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app

10.1093/rheumatology/keac161 · 2022 · External reference

Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy

10.1016/j.semarthrit.2021.03.018 · 2021 · External reference

Patient-reported outcomes in adult idiopathic inflammatory myopathies

10.1007/s11926-019-0862-5 · 2019 · External reference

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis

10.1136/annrheumdis-2017-211400 · 2017 · External reference

Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles

10.1093/rheumatology/kead110 · 2023 · External reference

Health-related quality of life improvements and response thresholds of myositis outcome measures and response criteria

2026 · External reference

Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients

10.1007/s10067-024-07120-1 · 2024 · External reference

The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis

10.1002/acr.20280 · 2010 · External reference

International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease

10.1093/rheumatology/keg427 · 2004 · External reference

Predictors of relapse of polymyositis/dermatomyositis associated interstitial lung disease

10.21037/jtd-23-1736 · 2024 · External reference

Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study

2026 · External reference

Myositis-specific autoantibodies: an important tool to support diagnosis of myositis

10.1111/joim.12451 · 2016 · External reference

Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis

10.1093/rheumatology/keq073 · 2010 · External reference

Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

10.1093/rheumatology/kes102 · 2012 · External reference

Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis

10.3109/s10165-010-0371-x · 2011 · External reference

Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies

10.3389/fimmu.2021.773352 · 2021 · External reference

Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease

10.1186/s13075-025-03675-9 · 2025 · External reference

Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias

10.1186/s12890-017-0479-2 · 2017 · External reference

The serum ferritin level is associated with the treatment responsivity for rapidly progressive interstitial lung disease with amyopathic dermatomyositis, irrespective of the anti-MDA5 antibody level

10.2169/internalmedicine.8335-16 · 2018 · External reference

Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis

10.1080/14397595.2018.1548918 · 2019 · External reference

An observational study on the clinical characteristics and prognosis of patients with interstitial lung disease secondary to dermatomyositis and antisynthetase syndrome

10.1155/2024/9679944 · 2024 · External reference

Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study

10.1136/annrheumdis-2012-202281 · 2013 · External reference

Definition of rheumatoid arthritis flare based on SDAI and CDAI

10.1136/ard-2023-224742 · 2024 · External reference

An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS

10.1136/annrheumdis-2017-212178 · 2018 · External reference

Classification and definition of major flares in SLE clinical trials

10.1191/096120399680411281 · 1999 · External reference

Establishing a consensus definition of VEXAS flare for clinical research

10.1093/rheumatology/keaf624 · 2026 · External reference

Systemic lupus erythematosus disease activity index 2000

2002 · External reference

Derivation of the SLEDAI. A disease activity index for lupus patients

10.1002/art.1780350606 · 1992 · External reference

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries

10.1136/annrheumdis-2018-214140 · 2019 · External reference

EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren’s syndrome

10.1136/ard.2010.143743 · 2011 · External reference

International consensus definition of disease flare in hidradenitis suppurativa

10.1111/bjd.21647 · 2022 · External reference

Discordance between patient-reported outcomes and mucosal inflammation in patients with mild to moderate ulcerative colitis

10.1016/j.cgh.2019.09.021 · 2020 · External reference

Classification in idiopathic inflammatory myopathies: where are we now?

10.1111/1756-185x.70295 · 2025 · External reference

Relapse rate after glucocorticoid-free remission in patients with idiopathic inflammatory myopathies and validation of the international myositis assessment and clinical studies group criteria for complete clinical response and worsening

10.1002/art.43429 · 2026 · External reference

Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study

2014 · External reference

Clinical features and risk factors of flare in anti-synthetase syndrome

10.1007/s10067-025-07398-9 · 2025 · External reference

High frequency of muscle activity relapses in anti-Jo-1 antisynthetase syndrome

10.1111/1756-185x.70469 · 2025 · External reference

A randomized, pilot trial of etanercept in dermatomyositis

10.1002/ana.22477 · 2011 · External reference

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial

10.1002/art.37754 · 2013 · External reference

Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial

10.1136/annrheumdis-2017-211751 · 2018 · External reference

A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis

10.1016/j.semarthrit.2017.10.010 · 2018 · External reference

Trial of intravenous immune globulin in dermatomyositis

10.1056/nejmoa2117912 · 2022 · External reference

Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis

10.1002/acr2.11493 · 2022 · External reference

Belimumab treatment of adult idiopathic inflammatory myopathy

10.1093/rheumatology/kead281 · 2024 · External reference